Opko Health, Inc.

305 articles about Opko Health, Inc.

• OPKO Health Reports First Quarter 2023 Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  5/3/2023

  OPKO Health, Inc. reports business highlights and financial results for the three months ended March 31, 2023.

• OPKO Health to Hold Virtual R&D Day on March 20, 2023

  3/9/2023

  OPKO Health, Inc. announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time.

• OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

  3/8/2023

  OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada, for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.

• OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

  2/23/2023

  OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022.

• OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

  2/16/2023

  OPKO Health, Inc. plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023.

• OPKO Health Reports Third Quarter 2022 Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  11/8/2022

  OPKO Health, Inc. reports business highlights and financial results for the three months ended September 30, 2022.

• OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022

  11/1/2022

  OPKO Health, Inc. plans to report operating and financial results for the three and nine months ended September 30, 2022 after the close of the U.S. financial markets on Tuesday, November 8, 2022.

• OPKO Health Announces Leadership Changes for BioReference Laboratories

  8/16/2022

  OPKO Health, Inc. today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO.

• OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results

  8/4/2022

  OPKO Health, Inc. reports business highlights and financial results for the three and six months ended June 30, 2022.

• OPKO Health to Present at the 2022 Jefferies Healthcare Conference

  6/2/2022

  OPKO Health, Inc. announced that management will be participating in the 2022 Jefferies Healthcare Conference taking place June 8-10, 2022 in New York City.

• OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

  5/9/2022

  OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases.

• OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

  5/5/2022

  OPKO Health, Inc. plans to report operating and financial results for the three months ended March 31, 2022 after the close of the U.S. financial markets on Monday, May 9, 2022.

• Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

  3/1/2022

  Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency who may be eligible to participate in a Phase 3 clinical trial.

• OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

  2/24/2022

  OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2021.

• OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

  2/17/2022

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financial markets on Thursday, February 24, 2022.

• Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

  2/15/2022

  Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

• RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

  2/3/2022

  OPKO Health, Inc. announces that Vifor Fresenius Medical Care Renal Pharma has initiated the commercial launch of RAYALDEE® in Germany, the first launch of RAYALDEE outside the U.S. VFMCRP is OPKO’s commercial partner for RAYALDEE in Europe and selected markets outside the U.S.

• 

  Pfizer and OPKO's Growth Hormone Deficiency Drug Denied by FDA

  1/24/2022

  FDA rejected OPKO's once-weekly human growth hormone, somatrogon, which it co-developed with Pfizer for the treatment of growth hormone deficiency (GHD) in pediatric patients.

• Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

  1/18/2022

  Sema4, an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company, announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc., a leader in genomic testing and analysis, from OPKO.

• OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  OPKO Health, Inc. announced that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.